The methylation levels of seven gene promoters (ANKDD1A, GAD1, SIX3, SST, PHOX2B, PCDHA8, and HIST1H3E) in glioma patients and cell lines were significantly higher than those in non-tumor controls (p < 0.01). Here, SIX3 is linked to neoplasm.